Volume 5- Issue 4: 2018 7255 ISSN: 2574-1241 DOI: 10.26717/BJSTR.2018.09.001828 P Prakash Babu. Biomed J Sci & Tech Res Research Article Biomedical Journal of Scientific & Technical Research (BJSTR) Open Access Introduction Glioblastoma are recognized as most aggressive and widespread malignancies of the brain. Irrespective of the multimodal treatment regime, prognosis still remains dismal. However, the clinical course appears to be heterogeneous ranging from 3 to 18 months [1,2]. The discrepancy in the prognosis is mainly attributed to few factors as age and presence of oligodendroglial component [2]. Necrosis and older age is often correlated with shorter survival in clinical cases [1]. Glioblastoma with oligodendroglial component (GBMO) are high grade astrocytic neoplasms with discrete oligodendroglial differentiation areas displaying necrosis [1]. Few studies have claimed that glioblastoma with oligodendroglial component display better prognostic pattern, yet this hypothesis remains controversial [3-8]. GBMOs have been reported to have distinct genetic alterations and clinical behavior and displays distinct IDH1 mutations along with 1p/19q co deletion [9,10]. In present study, we have observed the molecular signatures of p53 and MIB1 in GBMO patients. Further, we have also seen for the presence of necrosis pattern and prognostically evaluated the GBMO cases and compared it with survival of GBM patients. Materials and methods Selection of Patients The data of diagnosed clinical cases was collected from Krishna Institute of Medical Sciences, Secunderabad, India from 2009- 2014. Upon initial MRI diagnosis, the patients were followed for surgical resection. The resected tissues were followed for the histopathological diagnosis based on the criterion World Health Organization (WHO) as cellular proliferation, mitotic index, polymorphic nuclei and the presence of necrosis. 610 cases were found to be diagnosed with astrocytoma, out of which 40 were found with glioblastoma with oligodendroglial component. The selected patients were not having previous history of low grade Glioblastoma and Glioblastoma with Oligodendroglial Component: a Histological and Prognostic Overview Runing Head: pathology and GBM and GBMO Ravindra Pramod Deshpande 1 , Chandrasekhar YBVK 2 , Manas Panigrahi 2 , I Satish Rao 3 and Phanithi Prakash Babu 1 * 1 Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, India 2 Department of Neurosurgery, Krishna Institute of Medical Sciences, Secunderabad, India 3 Department of pathology, Krishna Institute of Medical Sciences, Secunderabad, India Received: : September 25, 2018; Published: : October 04, 2018 *Corresponding author: P Prakash Babu, Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad-500046. Telangana state, India Abstract Glioblastoma (GBM- GIV astrocytoma) represents the most noted neoplasms of the brain usually reported with dismal prognosis. The term glioblastoma with oligodendroglial component (GBMO) represents the present of oligodendroglial foci in glioblastoma tumors. GBMOs are usually represented with better therapeutic response and concomitant prognostic outcome. We have observed nearly 610 cases of various pathologic grades of astrocytoma from 2009 to 2014 and found the oligodendroglial component among the 40 cases. Nearly in all the cases of GBM and GBMOs received complete resection and was followed by standard therapeutic regime of radiotherapy and chemotherapy with temozolomide. The survival pattern was observed in patients diagnosed with GBM and GBMO. We have looked for the presence of MIB1, p53 and necrosis pattern in selected GBMO sub group. We observe nearly 54% of GBMOs stained positive with p53. Necrosis and MIB1 was observed in most of the GBMO cases. These was statistically significant difference among survival of glioblastoma patients’ and GBMOs. Glioblastoma multiformae patients with oligodendroglial component was observed to have median survival of 16 months while with GBM it was observed to be 12 months. GBMO were found to have significantly longer survival than glioblastoma patients’ and respond well to chemo and radiotherapy. Keywords: Glioblastoma; GBMO; P53; Mib1; Survival Abbreviations: GBMO: Glioblastoma with Oligodendroglial Component; WHO: World Health Organization; ICE: Institutional Ethics Committee; KFRC: KIMS Foundation Research Centre